Clinical pharmacology : proceedings of the 7th International Congress of Pharmacology, Paris, 1978

Clinical Pharmacology provides a detailed discussion on toxicology. This discussion includes the chemotherapy of parasitic diseases. Some parts of the book focus on topics on immunopharmacology. Such topic as the genetic and environmental factors that contribute to individual's varying response to drugs is explained. The book covers such topics as the methods and models for the isoniazid acetylation polymorphism. The issues that arise in the administration of drugs in the neonatal period are assessed. Another topic of interest is the effects of diseases on the absorption of drugs. The pharmacokinetic and pharmacodynamic characteristics of a drug are evaluated. The pharmacogenetic investigation amobarbital disposition is presented completely. The book then presents the use and consumption of drugs in different locations and some clinical considerations. The procedures and methods of analysis for such drug are also reviewed. The book can serve as a valuable tool for pharmacists, medical doctors, pediatricians, students, and researchers in the field of medicine. Content: ADVANCES IN PHARMACOLOGY AND THERAPEUTICS , Page ii Front Matter , Page iii Copyright , Page iv Introduction , Pages ix-x , Jacques R BOISSIER Genetic and Environmental Factors Responsible for Interindividual Variations in Drug Response , Pages 3-12 , Elliot S. Vesell Interindividual Differences in Plasma Concentrations and Effect of the Adrenergic Beta-receptor Blocking Drug Alprenolol and its Metabolite 4-hydroxy-alprenolol in Man , Pages 13-22 , Christer von Bahr, Karl-Olof Borg, Per Collste Interindividual Differences in Drug Response. Studies with Indomethacin and Oral Contraceptive Steroids , Pages 23-30 , M.L'E. Orme, N. Baber, D.J. Back, A.M. Breckenridge, L. Halliday, T. Littler Pharmacogenetic Investigation of Amobarbital Disposition , Pages 31-40 , W. Kalow, L. Endrenyi, T. Inaba, D. Kadar, B. Tang New Methods and Models for the Isoniazid Acetylation Polymorphism , Pages 41-50 , W. Weber, R. Tannen, C. McQueen, I. Glowinski Polymorphic Drug Acetylation and Systemic Lupus Erythematosus , Pages 51-56 , Marcus M. Reidenberg, Dennis E. Drayer, William C. Robbins Problems of Drugs Administration in the Neonatal Period , Pages 57-66 , Paolo Lucio Morselli The Effect of Disease on the Response to Drugs , Pages 67-76 , Roland Gugler Drug Utilization - Geographical Differences and Clinical Implications: INTRODUCTORY REMARKS , Pages 79-82 , P.K.M. Lunde, M. Levy Methodologies and Approaches in Drug Utilisation Studies , Pages 83-92 , Ludvík Štika Drug Prescribing in Hospitals: An International Comparison , Pages 93-99 , D.H. Lawson, H. Jick Drug Utilization Strategies within Regional Programs on Drug Control and Evaluation , Pages 101-112 , G. Tognoni, C. Bellantuono, F. Colombo, M.L. Farina, L. Ferrario, M.G. Franzosi, M. Mancini, M. Mandelli Drug Utilization — Geographical Differences and Clinical Implications — Psychotropic Drugs , Pages 113-121 , Barbro Westerholm, F. Kristensen, H.U. Schaffalitzky de Muckadell, J. Idänpään-Heikkilä, T. Lahti, A. Grimsson, O. Olaffson, C. McMeekin, P.K.M. Lunde, K. Oydvin Drug Utilization — Geographical Differences and Clinical Implications — Antidiabetic Drugs , Pages 123-132 , Ulf Bergman Antihypertensive Drugs , Pages 133-141 , Ingebjorg Baksaas Digoxin - Compliance as a Factor in Drug Utilisation , Pages 143-151 , Denis G. McDevitt, G. Dennis Johnston Drug Utilization, the Role and Effect of Clinical Pharmacology , Pages 153-159 , Micha Levy Controls of Drug Utilization: National and International Implications , Pages 161-168 , William M. Wardell Drug Utilization — Geographical Differences and Clinical Implications: CONCLUDING REMARKS , Pages 169-170 , M. Levy, P.K.M. Lunde Summary , Page 172 Surveillance of Drugs in Therapeutic Use , Pages 173-174 , Antal Káldor Registered Release: a Method for Detecting Adverse Drug Reactions , Pages 175-178 , C.T. Dollery Surveillance of Drugs in Therapeutic Use in Developing Countries , Pages 179-187 , U.K. Sheth Methods of “Audit” in Drug Use , Pages 189-195 , James Crooks The Value and Limitations of Patient Registers in Drug Surveillance , Pages 197-202 , Barbro Westerholm Experiences of the Boston Collaborative Drug Surveillance Program , Pages 203-207 , Hershel Jick Relevance of “in Vitro” Electrophysiologic Effects of Antiarrhythmic Drugs to their Efficacy under “in vivo” Conditions , Pages 211-219 , László Szekeres, Julius Gy. Papp Arrhythmias Caused by Cardiac Glycosides , Pages 221-230,235-236 , Mario Vassalle From Experiment to Therapeutic Application in the Field of Antiarrhythmics , Pages 237-244 , N.V. Kaverina Clinical use of Antiarrhythmic Drugs. The Relevance of Experimental Data , Pages 245-248 , Philippe Coumel New Antiarrhythmics. The need for bridging the gap between the pharmacologist and the clinician , Pages 249-256 , H.J.J. Wellens Theoretical Considerations Concerning Drug Treatment of Dysrhythmias due to Coronary Insufficiency , Pages 257-275 , László Szekeres Index , Pages 277-280 v. 1. Receptors v. 2. Neurotransmitters v. 3. Ions, cyclic nucleotides, cholinergy v. 4. Prostaglandins, immunopharmacology v. 5. Neuropsychopharmacology v. 6. Clinical pharmacology v. 7. Biochemical-clinical pharmacology v. 8. Drug-action modifications, comparative pharmacology v. 9. Toxicology v. 10. Chemotherapy.